Close

Target Deconvolution

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Surfarray™ cell microarray technology is well suited for target deconvolution. In particular, it is used to identify primary targets for macromolecules or small molecules that exhibit the desired biological or clinical effects. It ranges from the primary goal of revealing antibodies or small molecule compounds identified by phenotypic screening to commercially available drugs.

Creative Biolabs's unique and highly sensitive Surfarray™ cell microarray technology is widely used for CAR-T and antibody target deconvolution, which allows us to provide fast, accurate and efficient solutions to our customers around the world.

Discover:

  • Discover novel, high quality, and developable cell therapy targets
  • Receptor molecules are targeted by phenotypic molecules (antibodies, scFvs, Fc-fusion proteins, etc.)
  • Widely covered known plasma membranes and secreted protein subclasses
  • Identification of disease-specific antigens by screening patient sera

Key Features for Our Target Deconvolution

Extremely High Success Rate

To date, Creative Biolabs has accumulated extensive phenotypic molecular screening experience through several projects, including projects on "difficult" molecules. We have screened for specific, repeatable molecules with a success rate of more than 50% due to the extensive collection of membrane proteins expressed by human cells.

High Specificity

Surfarray™'s low false positive rate ensures that months or years of research are not wasted to chase dead ends when verifying potential target hits. Target deconvolution using Surfarray™ cell microarray technology typically produces one or two repeatable hits that are specific to the test molecule and typically represent the primary receptor target and its different isoforms.

Creative Biolabs is dedicated to helping our worldwide customers shorten the discovery and development time in CAR-T cell therapy. We utilize unrivaled, proprietary drug design, study data, product candidate, advanced project life-cycle management, as well as real-time data to ensure the ideal outcomes.

For more detailed information, please feel free to contact us or directly send us an inquiry.

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.